Distinct Fcγ Receptors Mediate the Effect of Serum Amyloid P on Neutrophil Adhesion and Fibrocyte Differentiation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The plasma protein serum amyloid P (SAP) reduces neutrophil adhesion, inhibits the differentiation of monocytes into fibroblast-like cells called fibrocytes, and promotes phagocytosis of cell debris by macrophages. Together, these effects of SAP reduce key aspects of inflammation and fibrosis, and SAP injections improve lung function in pulmonary fibrosis patients. SAP functions are mediated, in part, by FcγRs, but the contribution of each FcγR is not fully understood. We found that aa Q55 and E126 in human SAP affect human fibrocyte differentiation and SAP binding to FcγRI. E126, K130, and Q128 affect neutrophil adhesion and SAP affinity for FcγRIIa. Q128 also affects phagocytosis by macrophages and SAP affinity for FcγRI. All the identified functionally significant amino acids in SAP form a binding site that is distinct from the previously described SAP-FcγRIIa binding site. Blocking FcγRI with an IgG-blocking Ab reduces the SAP effect on fibrocyte differentiation, and ligating FcγRIIa with Abs reduces neutrophil adhesion. Together, these results suggest that SAP binds to FcγRI on monocytes to inhibit fibrocyte differentiation, and binds to FcγRIIa on neutrophils to reduce neutrophil adhesion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
Self-citationA neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice
Takemasa, A., Ishii, Y., & Fukuda, T. (2012) · European Respiratory Journal · doi:10.1183/09031936.00127011 · Cited by 140
Cited by
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Hepatocytes: a key cell type for innate immunity
Zhou, Z., Xu, M.-J., & Gao, B. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.97 · Cited by 472
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
The Development of Serum Amyloid P as a Possible Therapeutic
Pilling, D., & Gomer, R. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02328 · Cited by 92
“M1macrophages are highly aggressive against bacteria and other pathogens, but SAP, which is a constitutive component of the blood, pushes macrophages toward an anti-inflammatory/antifibrotic phenotype (90, 95, 99, 100, 103, 156, 167, 168).”
BackgroundSelf-citationPentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease
Nakagawa, N., Barron, L., Gomez, I. G., Johnson, B. G., Roach, A. M., Kameoka, S., Jack, R. M., Lupher, M. L., Gharib, S. A., & Duffield, J. S. (2016) · JCI Insight · doi:10.1172/jci.insight.87446 · Cited by 59
Metadata
- Authors
- Cox, N., Pilling, D., & Gomer, R. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08
- Volume
- 193
- Issue
- 4
- Pages
- 1701-1708
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2139744886
- Cited by
- 42
- References
- 4
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.